Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms AURAChinaPK
- Sponsors AstraZeneca
- 18 Jan 2018 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.
- 14 Dec 2017 Results published in the Journal of Clinical Pharmacology
- 13 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.